What was the rationale for using the SOX (S‑1 plus oxaliplatin) chemotherapy backbone in the Asteum 006 trial?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Rationale for SOX Chemotherapy Backbone in ASTRUM-006 Trial

The ASTRUM-006 trial selected SOX (S-1 plus oxaliplatin) as the chemotherapy backbone because it represents an established, effective, and well-tolerated standard regimen for locally advanced gastric cancer in Asian populations, with proven efficacy in both perioperative and adjuvant settings.

Evidence-Based Selection of SOX

Established Efficacy in Asian Populations

The SOX regimen was chosen based on robust phase III evidence demonstrating its effectiveness specifically in Asian patients with gastric cancer:

  • S-1 has proven superiority in Asian populations: The SPIRITS trial established S-1 plus cisplatin as superior to S-1 monotherapy, with median OS of 13 vs 11 months 1
  • Oxaliplatin-based regimens show comparable efficacy to cisplatin: Multiple trials (REAL-2, ML17032) demonstrated that oxaliplatin is as effective as cisplatin in gastroesophageal cancer 1, 2, 1
  • SOX specifically validated in Asian trials: The SOPP trial (phase III) confirmed SOX was non-inferior to S-1 plus cisplatin in metastatic/recurrent gastric cancer, with median PFS of 5.6 vs 5.7 months 3

Superior Safety Profile

Oxaliplatin offers significant toxicity advantages over cisplatin, which is critical for perioperative treatment where patients must tolerate both neoadjuvant and adjuvant therapy:

  • Reduced severe toxicities: Compared to cisplatin, oxaliplatin causes lower rates of grade 3-4 neutropenia, alopecia, renal toxicity, and thromboembolism 1
  • No nephrotoxicity concerns: Oxaliplatin eliminates the need for aggressive hydration protocols required with cisplatin 2
  • Better tolerability in elderly patients: FLO (fluorouracil, leucovorin, oxaliplatin) showed superior outcomes in patients >65 years compared to cisplatin-based regimens 1

Perioperative Setting Validation

The SOX regimen had specific evidence supporting its use in the perioperative context before ASTRUM-006:

  • RESOLVE trial demonstrated perioperative SOX efficacy: This phase III trial showed perioperative SOX significantly improved 3-year disease-free survival (HR 0.77) compared to adjuvant capecitabine plus oxaliplatin in locally advanced gastric cancer 4, 5
  • Adjuvant SOX approval in Japan: Following J-CLASSIC and SOX-adjuvant trials, S-1 plus oxaliplatin was approved as an adjuvant regimen 6
  • Feasibility in neoadjuvant setting: Phase I/II studies confirmed SOX could be safely administered preoperatively with acceptable toxicity and promising pathological response rates 7

Practical Advantages for Trial Design

Convenience and Compliance

  • Oral S-1 administration: Unlike infusional 5-FU, S-1 is taken orally, improving patient convenience and reducing central line complications 1
  • Simplified administration: The 3-week cycle (oxaliplatin day 1, S-1 days 1-14) is straightforward and well-established 3, 8
  • No hospitalization required: Outpatient administration feasible for most cycles

Regional Appropriateness

S-1 is particularly suited for Asian populations where ASTRUM-006 was conducted (China and Thailand):

  • S-1 is widely available and approved in Asian countries 6
  • Pharmacogenetic differences make S-1 better tolerated in Asian vs. non-Asian populations 9, 10
  • Extensive Asian experience with S-1-based regimens provides robust safety data 6

Alternative Regimens Considered

While other perioperative regimens exist, SOX offered specific advantages for this trial:

  • FLOT (5-FU, leucovorin, oxaliplatin, docetaxel): Though FLOT showed superior outcomes in Western populations, it has significantly higher toxicity (48% requiring dose adjustments in elderly patients) 4. The addition of taxanes increases neutropenia, stomatitis, and nausea without clear survival benefit in Asian populations 10

  • Capecitabine plus oxaliplatin (CapOx): While effective, the RESOLVE trial directly demonstrated SOX superiority over CapOx in the adjuvant setting 5

  • Cisplatin-based regimens: Higher toxicity profile makes them less suitable for perioperative treatment where cumulative toxicity is a concern 1, 2

Critical Considerations

The SOX backbone allowed ASTRUM-006 to isolate the immunotherapy effect: By using a well-established, effective chemotherapy regimen with known toxicity profiles, the trial could clearly attribute any additional benefit to serplulimab rather than variations in chemotherapy efficacy 8.

Common pitfall to avoid: Do not assume Western perioperative regimens (like FLOT) are automatically superior in Asian populations. Regional pharmacogenetic differences, drug availability, and population-specific efficacy data must guide regimen selection 6, 10.

The final RESOLVE trial data confirmed this choice was appropriate, showing 5-year OS of 60% with perioperative SOX, validating it as a standard treatment for locally advanced gastric cancer in Asian patients 5.

References

Guideline

gastric cancer.

Journal of the National Comprehensive Cancer Network : JNCCN, 2010

Guideline

gastric cancer, version 2.2022, nccn clinical practice guidelines in oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2022

Research

Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial).

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2021

Guideline

oesophageal cancer.

Nature Reviews Disease Primers, 2017

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.